Literature DB >> 33420352

CD226: a potent driver of antitumor immunity that needs to be maintained.

Jiacheng Bi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33420352      PMCID： PMC9424278          DOI： 10.1038/s41423-020-00633-0

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   22.096


× No keyword cloud information.
  10 in total

Review 1.  Balancing natural killer cell activation through paired receptors.

Authors:  Ludovic Martinet; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2015-03-06       Impact factor: 53.106

2.  Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.

Authors:  Stephen J Blake; Kimberley Stannard; Jing Liu; Stacey Allen; Michelle C R Yong; Deepak Mittal; Amelia Roman Aguilera; John J Miles; Viviana P Lutzky; Lucas Ferrari de Andrade; Ludovic Martinet; Marco Colonna; Kazuyoshi Takeda; Florian Kühnel; Engin Gurlevik; Günter Bernhardt; Michele W L Teng; Mark J Smyth
Journal:  Cancer Discov       Date:  2016-01-19       Impact factor: 39.397

3.  Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.

Authors:  Qing Zhang; Jiacheng Bi; Xiaodong Zheng; Yongyan Chen; Hua Wang; Wenyong Wu; Zhengguang Wang; Qiang Wu; Hui Peng; Haiming Wei; Rui Sun; Zhigang Tian
Journal:  Nat Immunol       Date:  2018-06-18       Impact factor: 25.606

4.  The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.

Authors:  Robert J Johnston; Laetitia Comps-Agrar; Jason Hackney; Xin Yu; Mahrukh Huseni; Yagai Yang; Summer Park; Vincent Javinal; Henry Chiu; Bryan Irving; Dan L Eaton; Jane L Grogan
Journal:  Cancer Cell       Date:  2014-11-26       Impact factor: 31.743

Review 5.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

Review 6.  Tumor intrinsic and extrinsic immune functions of CD155.

Authors:  Jake S O'Donnell; Jason Madore; Xian-Yang Li; Mark J Smyth
Journal:  Semin Cancer Biol       Date:  2019-12-26       Impact factor: 15.707

7.  Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs.

Authors:  K Morimoto; K Satoh-Yamaguchi; A Hamaguchi; Y Inoue; M Takeuchi; M Okada; W Ikeda; Y Takai; T Imai
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

8.  CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.

Authors:  Xian-Yang Li; Indrajit Das; Ailin Lepletier; Venkateswar Addala; Tobias Bald; Kimberley Stannard; Deborah Barkauskas; Jing Liu; Amelia Roman Aguilera; Kazuyoshi Takeda; Matthias Braun; Kyohei Nakamura; Sebastien Jacquelin; Steven W Lane; Michele Wl Teng; William C Dougall; Mark J Smyth
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

9.  Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.

Authors:  Marianne Weulersse; Assia Asrir; Andrea C Pichler; Lea Lemaitre; Matthias Braun; Nadège Carrié; Marie-Véronique Joubert; Marie Le Moine; Laura Do Souto; Guillaume Gaud; Indrajit Das; Elisa Brauns; Clara M Scarlata; Elena Morandi; Ashmitha Sundarrajan; Marine Cuisinier; Laure Buisson; Sabrina Maheo; Sahar Kassem; Arantxa Agesta; Michaël Pérès; Els Verhoeyen; Alejandra Martinez; Julien Mazieres; Loïc Dupré; Thomas Gossye; Vera Pancaldi; Camille Guillerey; Maha Ayyoub; Anne S Dejean; Abdelhadi Saoudi; Stanislas Goriely; Hervé Avet-Loiseau; Tobias Bald; Mark J Smyth; Ludovic Martinet
Journal:  Immunity       Date:  2020-10-13       Impact factor: 43.474

10.  CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.

Authors:  Matthias Braun; Amelia Roman Aguilera; Ashmitha Sundarrajan; Dillon Corvino; Kimberley Stannard; Sophie Krumeich; Indrajit Das; Luize G Lima; Lizeth G Meza Guzman; Kunlun Li; Rui Li; Nazhifah Salim; Maria Villancanas Jorge; Sunyoung Ham; Gabrielle Kelly; Frank Vari; Ailin Lepletier; Ashwini Raghavendra; Sally Pearson; Jason Madore; Sebastien Jacquelin; Maike Effern; Brodie Quine; Lambros T Koufariotis; Mika Casey; Kyohei Nakamura; Eun Y Seo; Michael Hölzel; Matthias Geyer; Glen Kristiansen; Touraj Taheri; Elizabeth Ahern; Brett G M Hughes; James S Wilmott; Georgina V Long; Richard A Scolyer; Martin D Batstone; Jennifer Landsberg; Dimo Dietrich; Oltin T Pop; Lukas Flatz; William C Dougall; André Veillette; Sandra E Nicholson; Andreas Möller; Robert J Johnston; Ludovic Martinet; Mark J Smyth; Tobias Bald
Journal:  Immunity       Date:  2020-10-13       Impact factor: 43.474
  10 in total
  1 in total

1.  Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients.

Authors:  Lena Peter; Désirée Jacqueline Wendering; Stephan Schlickeiser; Henrike Hoffmann; Rebecca Noster; Dimitrios Laurin Wagner; Ghazaleh Zarrinrad; Sandra Münch; Samira Picht; Sarah Schulenberg; Hanieh Moradian; Mir-Farzin Mashreghi; Oliver Klein; Manfred Gossen; Toralf Roch; Nina Babel; Petra Reinke; Hans-Dieter Volk; Leila Amini; Michael Schmueck-Henneresse
Journal:  Mol Ther Methods Clin Dev       Date:  2022-02-26       Impact factor: 6.698
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.